PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ambroxol→

Ambroxol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
18683-91-5
Molecular formula
C13H18Br2N2O
Molecular weight
378.1 g/mol
Drug class
Mucolyticsecretolytic and mucokinetic agent (bromhexine metabolite)
Mechanism of action
The precise mechanism is not fully elucidated. Ambroxol increases serous respiratory secretion, stimulates ciliary activity and mucociliary clearance, and activates pulmonary surfactant production, helping reduce mucus viscosity and facilitate expectoration.
Indications / reported uses
  • Expectorant use in acute and chronic respiratory conditions with abnormal viscid mucus, where authorised
  • Lozenge formulations may be used for sore throat; injectable uses and indications differ by product and jurisdiction

Sources: European Medicines Agency (EMA) referral · Spanish Agency of Medicines (AEMPS) SmPC

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ambroxol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ambroxol Permitted Daily Exposure (PDE) report (the Ambroxol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ambroxol Occupational Exposure Limit (OEL) report (the Ambroxol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.